Stocks

Headlines

Ligand Pharmaceuticals Forecasts EPS of $6.00 to $6.25

Biopharmaceutical company Ligand Pharmaceuticals reports a fourth-quarter loss but confirms its fiscal 2025 forecast. Despite a dip in profit, adjusted earnings projections remain positive.

Date: 
AI Rating:   5

Earnings Per Share (EPS)
Ligand Pharmaceuticals specified an adjusted EPS forecast for fiscal 2025 ranging from $6.00 to $6.25. The analysts' average expectation for EPS is $6.14, which is within the company’s range, suggesting a positive outlook.

Revenue Growth
In the fourth quarter, Ligand experienced revenue growth, reporting $42.81 million compared to $28.10 million from the same period last year, exceeding analysts’ expectations of $39.03 million.

Net Income
The company reported a net loss of $31.09 million for the fourth quarter against a profit of $18.19 million from the previous year. This is a significant negative turn; however, it's essential to understand this in conjunction with future guidance.

Free Cash Flow (FCF)
There are no specifics provided in the report regarding Free Cash Flow.

Return on Equity (ROE)
Return on Equity details are not mentioned in the report.

Overall, while the report indicates a fourth-quarter net loss, the positive adjustments in EPS forecasts and substantial revenue growth may have a balancing effect on investor perceptions.

Stocks:  LGND